The Drugs That Could Slow Aging Are Already Here | Dr. Nir Barzilai

Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: https://rechargehealthas.sjv.io/jRQyQ5 ---------- Guests: Nir Barzilai Director of the Institute for Aging Research at the Albert Einstein College of Medicine LinkedIn: https://www.linkedin.com/in/nir-barzilai-7a86a7212/ Link to Nir's works: https://einsteinmed.edu/faculty/484/nir-barzilai, https://www.sciencedirect.com/author/7005711408/nir-barzilai ---------- What if aging itself is the biggest medical opportunity of the 21st century? Phil Newman and Dr. Nina Patrick sit down with Dr. Nir Barzilai, physician-scientist, professor of medicine and genetics, founding director of the Institute for Aging Research at Albert Einstein College of Medicine, and one of the pioneers of geroscience, to explore why targeting the biology of aging could delay multiple diseases at once. Together they explain how decades of centenarian research revealed that healthy longevity is biologically achievable. From centenarians who remain healthy until their final year of life to real-world evidence showing GLP-1 therapies can reduce hospitalization and mortality, these insights are reshaping modern medicine. They also discuss metformin, SGLT2 inhibitors, biological age testing, longevity biomarkers, regulatory progress at the FDA, and the future of aging therapeutics. Barzilai shares the scientific foundations behind the geroscience hypothesis, the idea that aging itself is the major driver of chronic disease. He explains why interventions that target aging biology may offer broader benefits than treating diseases one by one, and how decades of research have shifted the conversation from lifespan extension toward extending healthspan and compressing morbidity. The discussion also explores the challenges facing the longevity field, from supplement overuse and biomarker validation to clinical trial design and regulatory pathways. Barzilai offers his perspective on emerging therapies, the promise of biological age measurement, and why the next generation of longevity medicine may look very different from today's healthcare model. In this episode, you’ll learn: - Why aging biology drives diseases like Alzheimer's, diabetes, and cardiovascular disease - How centenarians compress morbidity and remain healthy into extreme old age - Why GLP-1 therapies reduced hospitalization and death by roughly 60% in one study - Why Barzilai tracks proteomics and believes biomarkers will transform longevity medicine - Which longevity interventions he personally uses, including metformin and Rejuvant If you want to understand how aging science is moving from theory to clinical reality, this episode connects cutting-edge research with practical insights for extending human healthspan. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better. ---------- 00:00:00 - The Geroscience Pioneer 00:02:01 - Nir's Longevity Stack 00:05:19 - What Is Geroscience? 00:10:14 - Why Healthspan Saves Money 00:14:27 - Lessons From Centenarians 00:16:58 - Which Drugs Extend Healthspan? 00:23:13 - Who Should Take Metformin? 00:25:48 - GLP-1s And Aging 00:35:44 - The Biomarker Revolution 00:40:03 - What Comes Next? 00:42:35 - Why Nir Takes Rejuvant 00:45:28 - Supplement Risks Explained 00:47:37 - FDA And Longevity Regulation 00:56:42 - Rapid Fire Insights 00:58:32 - The Next Decade Of Aging Biotech